<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01143025</url>
  </required_header>
  <id_info>
    <org_study_id>AR HSG 01 2010</org_study_id>
    <nct_id>NCT01143025</nct_id>
  </id_info>
  <brief_title>Intraperitoneal Ropivacaine Nebulization for Pain Control After Laparoscopic Surgery</brief_title>
  <official_title>Peritoneal Nebulization of Ropivacaine for Postoperative Pain Control After Laparoscopic Cholecystectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>San Gerardo Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Milano Bicocca</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>IRCCS Policlinico S. Matteo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda L'ULSS 15 Alta Padovana</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gruppo Ospedaliero San Donato, Policlinico San Pietro, Ponte San Pietro, Bergamo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda U.S.L. della Valle d'Aosta, Ospedale Regionale Umberto Parini</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>San Gerardo Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess if intraperitoneal nebulization of Ropivacaine 50 mg,
      100 mg or 150 mg may prevent the use of morphine during the first day after laparoscopic
      cholecystectomy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intraperitoneal aerosolization of Bupivacaine 50 mg after laparoscopic cholecystectomy has
      been proved to significantly reduce postoperative pain, morphine consumption and incidence of
      postoperative nausea and vomiting in comparison with patients receiving direct instillation
      of Bupivacaine 50 mg or placebo.

      Ropivacaine can be effectively administrated with non-heating nebulizers (AeronebPro®). In a
      recent study our group found that nebulization of Ropivacaine 30 mg with the AeronebPro®
      before or after laparoscopic cholecystectomy significantly reduced postoperative pain and
      morphine consumption. Nonetheless, most patients still need strong opioid based analgesia
      after surgery.

      We hypothesize that intraperitoneal nebulization of Ropivacaine 100 mg and 150 mg (maximum
      recommended dose in adults 300 mg or up to 3 mg/kg) may prevent the use of morphine during
      the first day after surgery maintaining ropivacaine plasma levels below toxic concentration.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Morphine consumption (mg)</measure>
    <time_frame>Up to 48 hours</time_frame>
    <description>The total dose of morphine at every evaluation after awakening will be quantified using the PACU clinical chart and/or PCA infusers memory display</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ropivacaine pharmacokinetics profile: Plasma Concentration of Ropivacaine</measure>
    <time_frame>Up to 360 minutes</time_frame>
    <description>We will perform a pharmacokinetic analysis through venous samples collected at 20, 40, 60, 90, 240, and 360 minutes after the end of nebulization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ropivacaine pharmacokinetics profile: Tissue drug analysis</measure>
    <time_frame>Up to 2 hours</time_frame>
    <description>Tissue samples (at least 2 g of tissue) from parietal peritoneum will be taken at the end of surgery . The supernatant will be analised with mass-spectrometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative Pain</measure>
    <time_frame>Up to 48 hours</time_frame>
    <description>Postoperative pain will be assessed by numeric ranking scale (NRS 0 to 10 points) at rest (static NRS) and after a deep inspiration or cough (dynamic NRS). Pain after surgery will be differentiated as abdominal, wall pain, port wound pain and/or shoulder pain. The proportion of patients with adequate pain control after surgery (dynamic NRS &lt; 3) will also be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of unassisted walking</measure>
    <time_frame>Up to 48 hours</time_frame>
    <description>Unassisted walking time is defined as the time in hours between PACU discharge and when the patient is able to walk out of his room and back to bed without any assistance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital morbidity</measure>
    <time_frame>Up to 48 hours</time_frame>
    <description>All complications or adverse effects associated or possibly associated with the interventions under study, surgery or anesthesia will be quantified using the anesthesia charts, surgical charts, surgical database.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time and condition for hospital discharge</measure>
    <time_frame>Up to 48 hours</time_frame>
    <description>We define hospital stay as the elapsed time between surgery and hospital discharge, in days. We also evaluate the hospital stay with the post-anesthetic discharge scoring system (Modified-PADSS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life after surgery</measure>
    <time_frame>Four weeks after surgery</time_frame>
    <description>Quality of life will be assessed using the SF-36 questionnaire</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">165</enrollment>
  <condition>Laparoscopic Cholecystectomy</condition>
  <arm_group>
    <arm_group_label>Ropivacaine 50 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Preoperative nebulization of 50 mg of Ropivacaine in the peritoneal cavity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ropivacaine 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Preoperative nebulization of 100 mg of Ropivacaine in the peritoneal cavity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ropivacaine 150 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Preoperative nebulization of 150 mg of Ropivacaine in the peritoneal cavity</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine 50 mg</intervention_name>
    <description>Preoperative nebulization of 50 mg of Ropivacaine in the peritoneal cavity</description>
    <arm_group_label>Ropivacaine 50 mg</arm_group_label>
    <other_name>Nebulization</other_name>
    <other_name>Ropivacaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine 100 mg</intervention_name>
    <description>Preoperative nebulization of 100 mg of Ropivacaine in the peritoneal cavity</description>
    <arm_group_label>Ropivacaine 100 mg</arm_group_label>
    <other_name>Nebulization</other_name>
    <other_name>Ropivacaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine 150 mg</intervention_name>
    <description>Preoperative nebulization of 150 mg of Ropivacaine in the peritoneal cavity</description>
    <arm_group_label>Ropivacaine 150 mg</arm_group_label>
    <other_name>Nebulization</other_name>
    <other_name>Ropivacaine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Females and Males 18-75 years old

          -  ASA Score I-III

          -  Scheduled for laparoscopic cholecystectomy

          -  Free from pain in preoperative period

          -  Not using analgesic drugs before surgery

          -  Without cognitive impairment or mental retardation

          -  Written informed consent

        Exclusion Criteria:

          -  Emergency/urgency surgery

          -  Postoperative admission in an intensive care unit

          -  Cognitive impairment or mental retardation

          -  Progressive degenerative diseases of the CNS

          -  Seizures or chronic therapy with antiepileptic drugs

          -  Severe hepatic or renal impairment

          -  Pregnancy or lactation

          -  Allergy to one of the specific drugs under study

          -  Acute infection or inflammatory chronic disease

          -  Alcohol or drug addiction
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Massimo Allegri, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Servizio Anestesia e Rianimazione I e Terapia del Dolore, Fondazione IRCCS Policlinico San Matteo, Pavia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mario Regazzi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Head of Clinical PK and TDM Laboratory, Foundation IRCCS Policlinico San Matteo, Pavia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ernesto Pizzirani, MD</last_name>
    <role>Study Chair</role>
    <affiliation>U.O.C. Anestesia e Rianimazione. A.O. U.L.S.S.15 &quot;Alta Padovana&quot;, Presidio Camposampiero. Camposampiero - Padova</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fiorenza Franceschi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>U.O.C. Anestesia e Rianimazione. A.O. U.L.S.S.15 &quot;Alta Padovana&quot;, Presidio Camposampiero. Camposampiero - Padova</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Armando Alborghetti, MD</last_name>
    <role>Study Chair</role>
    <affiliation>U.O.C. Anestesia e Rianimazione. Ospedale di Ponte San Pietro. Bergamo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alessandro Albani, MD</last_name>
    <role>Study Chair</role>
    <affiliation>U.O. Anestesia e Rianimazione. Ospedale Regionale &quot;U. Parini&quot;, Aosta</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pierre Diemusch, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Servizio di Anestesia e rianimazione chirurgica. Hospital de Hautepierre. Università di Strasburgo.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>San Gerardo Hospital</name>
      <address>
        <city>Monza</city>
        <state>MB</state>
        <zip>20052</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Greib N, Schlotterbeck H, Dow WA, Joshi GP, Geny B, Diemunsch PA. An evaluation of gas humidifying devices as a means of intraperitoneal local anesthetic administration for laparoscopic surgery. Anesth Analg. 2008 Aug;107(2):549-51. doi: 10.1213/ane.0b013e318176fa1c.</citation>
    <PMID>18633034</PMID>
  </reference>
  <reference>
    <citation>Schlotterbeck H, Schaeffer R, Dow WA, Diemunsch P. Cold nebulization used to prevent heat loss during laparoscopic surgery: an experimental study in pigs. Surg Endosc. 2008 Dec;22(12):2616-20. doi: 10.1007/s00464-008-9841-z. Epub 2008 Mar 18.</citation>
    <PMID>18347861</PMID>
  </reference>
  <results_reference>
    <citation>Alkhamesi NA, Peck DH, Lomax D, Darzi AW. Intraperitoneal aerosolization of bupivacaine reduces postoperative pain in laparoscopic surgery: a randomized prospective controlled double-blinded clinical trial. Surg Endosc. 2007 Apr;21(4):602-6. Epub 2006 Dec 16.</citation>
    <PMID>17180268</PMID>
  </results_reference>
  <verification_date>May 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 9, 2010</study_first_submitted>
  <study_first_submitted_qc>June 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2010</study_first_posted>
  <last_update_submitted>May 18, 2011</last_update_submitted>
  <last_update_submitted_qc>May 18, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 19, 2011</last_update_posted>
  <responsible_party>
    <name_title>Pablo M Ingelmo, MD</name_title>
    <organization>First Service of anesthesia and intensive care. San Gerardo Hospital</organization>
  </responsible_party>
  <keyword>Laparoscopic Cholecystectomy</keyword>
  <keyword>Nebulization</keyword>
  <keyword>Ropivacaine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

